The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...

Drugmakers will be expected to commit to aligning U.S. prices with the lowest price set in a group of peer nations for all ...

Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

The late-stage results come in advance of pivotal data that Ionis expects to provide for its antisense oligonucleotide ...

In an interview on Friday, FDA Commissioner Marty Makary threw his weight behind psychedelic therapies, noting that patients ...

The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...

In a year when eradicated diseases are on the uptick in America, how will American children survive RFK Jr.’s vaccine ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Govorestat failed to meet its primary endpoint in a Phase II/III trial for a rare form of Charcot-Marie-Tooth disease, a few ...